FDA Webview
X

Free FDA Notices

Review Period Set for Stendra

06/10/2014

Federal Register Notice: FDA has determined the regulatory review period for Mitsubishi Tanabe Pharma Corp.’s Stendra (avanafil) is 3,770 days for extending a patent which claims the human drug product. FDA has approved for marketing the human drug product Stendra is indicated for treating erectile dysfunction. To view this notice, click here.

LATEST NEWS